H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more
H. Lundbeck A/S (HLBBF) - Net Assets
Latest net assets as of December 2025: $24.85 Billion USD
Based on the latest financial reports, H. Lundbeck A/S (HLBBF) has net assets worth $24.85 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($53.89 Billion) and total liabilities ($29.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $24.85 Billion |
| % of Total Assets | 46.11% |
| Annual Growth Rate | 5.65% |
| 5-Year Change | 35.93% |
| 10-Year Change | 156.31% |
| Growth Volatility | 12.9 |
H. Lundbeck A/S - Net Assets Trend (2004–2025)
This chart illustrates how H. Lundbeck A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for H. Lundbeck A/S (2004–2025)
The table below shows the annual net assets of H. Lundbeck A/S from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $24.85 Billion | -0.65% |
| 2024-12-31 | $25.01 Billion | +13.45% |
| 2023-12-31 | $22.05 Billion | +6.09% |
| 2022-12-31 | $20.78 Billion | +13.68% |
| 2021-12-31 | $18.28 Billion | +7.69% |
| 2020-12-31 | $16.97 Billion | +16.62% |
| 2019-12-31 | $14.55 Billion | +2.13% |
| 2018-12-31 | $14.25 Billion | +16.99% |
| 2017-12-31 | $12.18 Billion | +25.66% |
| 2016-12-31 | $9.69 Billion | +10.35% |
| 2015-12-31 | $8.79 Billion | -35.05% |
| 2014-12-31 | $13.53 Billion | +0.33% |
| 2013-12-31 | $13.48 Billion | +2.14% |
| 2012-12-31 | $13.20 Billion | +3.30% |
| 2011-12-31 | $12.78 Billion | +14.87% |
| 2010-12-31 | $11.12 Billion | +26.34% |
| 2009-12-31 | $8.80 Billion | +15.95% |
| 2008-12-31 | $7.59 Billion | +5.66% |
| 2007-12-31 | $7.18 Billion | +6.21% |
| 2006-12-31 | $6.76 Billion | -9.70% |
| 2005-12-31 | $7.49 Billion | -4.43% |
| 2004-12-31 | $7.84 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to H. Lundbeck A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 268.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $24.56 Billion | 98.84% |
| Common Stock | $993.74 Million | 4.00% |
| Other Comprehensive Income | $-704.40 Million | -2.84% |
| Total Equity | $24.85 Billion | 100.00% |
H. Lundbeck A/S Competitors by Market Cap
The table below lists competitors of H. Lundbeck A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Porto Seguro S.A
SA:PSSA3
|
$1.48 Billion |
|
HKBN Ltd
PINK:HKBNY
|
$1.48 Billion |
|
Six Flags Entertainment Corporation
NYSE:FUN
|
$1.48 Billion |
|
Eurocommercial Properties N.V.
AS:ECMPA
|
$1.48 Billion |
|
Alphatec Holdings Inc
NASDAQ:ATEC
|
$1.48 Billion |
|
X Trade Brokers Dom Maklerski SA
WAR:XTB
|
$1.48 Billion |
|
Hilltop Holdings Inc
NYSE:HTH
|
$1.48 Billion |
|
Northeast Securities Co Ltd
SHE:000686
|
$1.48 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in H. Lundbeck A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,010,000,000 to 24,846,593,000, a change of -163,407,000 (-0.7%).
- Net income of 3,184,770,000 contributed positively to equity growth.
- Dividend payments of 940,864,053 reduced retained earnings.
- Share repurchases of 19,954,698 reduced equity.
- Other comprehensive income decreased equity by 2,384,401,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $3.18 Billion | +12.82% |
| Dividends Paid | $940.86 Million | -3.79% |
| Share Repurchases | $19.95 Million | -0.08% |
| Other Comprehensive Income | $-2.38 Billion | -9.6% |
| Other Changes | $-2.96 Million | -0.01% |
| Total Change | $- | -0.65% |
Book Value vs Market Value Analysis
This analysis compares H. Lundbeck A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.19x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $34.11 | $4.85 | x |
| 2005-12-31 | $33.29 | $4.85 | x |
| 2006-12-31 | $32.05 | $4.85 | x |
| 2007-12-31 | $35.05 | $4.85 | x |
| 2008-12-31 | $38.57 | $4.85 | x |
| 2009-12-31 | $44.89 | $4.85 | x |
| 2010-12-31 | $56.71 | $4.85 | x |
| 2011-12-31 | $65.15 | $4.85 | x |
| 2012-12-31 | $67.29 | $4.85 | x |
| 2013-12-31 | $68.72 | $4.85 | x |
| 2014-12-31 | $68.87 | $4.85 | x |
| 2015-12-31 | $44.66 | $4.85 | x |
| 2016-12-31 | $49.11 | $4.85 | x |
| 2017-12-31 | $61.59 | $4.85 | x |
| 2018-12-31 | $71.71 | $4.85 | x |
| 2019-12-31 | $73.24 | $4.85 | x |
| 2020-12-31 | $85.41 | $4.85 | x |
| 2021-12-31 | $18.40 | $4.85 | x |
| 2022-12-31 | $20.93 | $4.85 | x |
| 2023-12-31 | $22.22 | $4.85 | x |
| 2024-12-31 | $25.21 | $4.85 | x |
| 2025-12-31 | $25.04 | $4.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently H. Lundbeck A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.82%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.11%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 2.17x
- Recent ROE (12.82%) is above the historical average (11.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 21.79% | 17.56% | 0.85x | 1.47x | $924.66 Million |
| 2005 | 21.02% | 17.36% | 0.78x | 1.55x | $825.23 Million |
| 2006 | 16.36% | 12.00% | 0.79x | 1.72x | $430.42 Million |
| 2007 | 24.63% | 16.11% | 0.89x | 1.72x | $1.05 Billion |
| 2008 | 21.90% | 14.74% | 0.89x | 1.66x | $903.81 Million |
| 2009 | 22.80% | 14.60% | 0.80x | 1.95x | $1.13 Billion |
| 2010 | 22.17% | 16.70% | 0.82x | 1.62x | $1.35 Billion |
| 2011 | 17.86% | 14.26% | 0.78x | 1.61x | $1.00 Billion |
| 2012 | 8.83% | 7.87% | 0.69x | 1.63x | $-154.80 Million |
| 2013 | 6.34% | 5.60% | 0.65x | 1.75x | $-493.10 Million |
| 2014 | -1.13% | -1.14% | 0.53x | 1.90x | $-1.51 Billion |
| 2015 | -64.82% | -39.02% | 0.68x | 2.43x | $-6.57 Billion |
| 2016 | 12.49% | 7.75% | 0.77x | 2.08x | $241.60 Million |
| 2017 | 21.54% | 15.23% | 0.87x | 1.62x | $1.41 Billion |
| 2018 | 27.42% | 21.86% | 0.78x | 1.61x | $2.48 Billion |
| 2019 | 15.89% | 13.33% | 0.49x | 2.46x | $857.60 Million |
| 2020 | 9.31% | 8.95% | 0.49x | 2.12x | $-116.30 Million |
| 2021 | 7.21% | 8.09% | 0.47x | 1.90x | $-509.90 Million |
| 2022 | 9.22% | 10.50% | 0.49x | 1.80x | $-161.90 Million |
| 2023 | 10.39% | 11.50% | 0.53x | 1.70x | $85.50 Million |
| 2024 | 12.57% | 14.28% | 0.39x | 2.28x | $642.00 Million |
| 2025 | 12.82% | 13.11% | 0.45x | 2.17x | $700.11 Million |
Industry Comparison
This section compares H. Lundbeck A/S's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| H. Lundbeck A/S (HLBBF) | $24.85 Billion | 21.79% | 1.17x | $1.48 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |